Brain Cancer Clinical Trials in Baltimore

Showing 101-120 of 123 trials

Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma

NCT00979862

This phase I trial is studying the side effects and best dose of cediranib maleate when given together with cilengitide in treating patients with progressive or recurrent glioblastoma. Cediranib maleate and cilengitide may stop the growth of tumor cells by blocking blood flow to the tumor. Giving cediranib maleate together with cilengitide may kill more tumor cells.

Adult Giant Cell GlioblastomaAdult GlioblastomaAdult Gliosarcoma+1 more

National Cancer Institute (NCI)47 participantsStarted Mar 2010

Birmingham, Alabama, United States • Atlanta, Georgia, United States • Baltimore, Maryland, United States +8 more locations

COMPLETEDPHASE1< 1 mile

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Brain Stem Glioma

NCT00003625

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one chemotherapy drug with radiation therapy may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy plus radiation therapy in treating patients with newly diagnosed brain stem glioma.

Brain TumorsCentral Nervous System Tumors

Children's Oncology Group7 participantsStarted Dec 1998

Birmingham, Alabama, United States • Tucson, Arizona, United States • Little Rock, Arkansas, United States +71 more locations

Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Brain Stem Glioma

Brain Cancer Trials in Other Cities

Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma

Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma

Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Bortezomib in Treating Patients With Recurrent Glioma

A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma

Comparison of TransMID vs Standard Treatment of Cancerous Brain Tumors

A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas

Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors

Sunitinib to Treat Recurrent Brain Cancer

The Role of Gene Changes in Brain Tumor Formation and Growth

AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors

Phase I/II Trial of Intracerebral IL13-PE38QQR Infusions in Pediatric Patients With Recurrent Malignant Glioma

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors

Carboplatin and Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy in Treating Young Patients With Newly Diagnosed CNS Embryonal Tumors

A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma

A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas

Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients

Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM)

Other Conditions in Baltimore